Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS

Neurology

Volumn 74, Issue 22, 2010, Pages 1822-1826

  Kingwell, E ^a   Koch, M ^a,d   Leung, B ^a   Isserow, S ^b   Geddes, J ^c   Rieckmann, P ^a   Tremlett, H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Vancouver Coastal Health ^*  (Canada)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOLASETRON MESILATE; METHYLPREDNISOLONE; MITOXANTRONE;

ADULT; ADVERSE OUTCOME; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; CANADA; CARDIOTOXICITY; DISEASE DURATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK POPULATION; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGE FACTORS; ANALGESICS; ANEMIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS; NEUTROPENIA; RETROSPECTIVE STUDIES; SEX FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77953206986     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181e0f7e6     Document Type: Article

References (21)

1. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neuro-surg Psychiatry 1997;62:112-118.
2. Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-159.
3. van de Wyngaert FA, Beguin C, D'Hooghe MB, et al. A double-blind clinical trial of mitoxantrone versus methyl-prednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg 2001;101:210-216.
4. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360:2018-2025.
5. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22:263-302.
6. Mather FJ, Simon RM, Clark GM, Von Hoff DD. Car-diotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies. Cancer Treat Rep 1987;71:609-613.
7. Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002;59:909-913.
8. Mauch E, Kornhuber HH, Krapf H, Fetzer U, Laufen H. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 1992;242:96-102.
9. Cohen BA, Mikol DD. Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 2004;63: S28-S32.
10. Jeffery DR. The argument against the use of cyclophosph-amide and mitoxantrone in the treatment of multiple sclerosis. J Neurol Sci 2004;223:41-46.
11. Hamzehloo A, Etemadifar M. Mitoxantrone-induced car-diotoxicity in patients with multiple sclerosis. Arch Iran Med 2006;9:111-114.
12. Avasarala JR, Cross AH, Clifford DB, Singer BA, Siegel BA, Abbey EE. Rapid onset mitoxantrone-induced cardio-toxicity in secondary progressive multiple sclerosis. Mult Scler 2003;9:59-62.
13. Paul F, Dorr J, Wurfel J, Vogel HP, Zipp F. Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2007;78:198-200.
14. Hum S, Lapierre Y. A clinical retrospective report on mi-toxantrone treatment in active multiple sclerosis patients. Neurology 2009;72:A237. Abstract.
15. Rivera V, Weinstock-Guttman B, Beagan J, Bennet R, Al-Sabbagh A, Dangond F. Final results from the registry to evaluate Novantrone. Mult Scler 2009;15:S254. Abstract.
16. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2009. Available at: http://evs.nci.nih.gov/ftp1/ CTCAE/CTCAE-4.02-2009-09-15-QuickReference- 8.5x11.pdf. Accessed January 19 2010.
17. Zingler VC, Nabauer M, Jahn K, et al. Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis. Eur Neurol 2005;54:28-33.
18. Le Page E, Leray E, Taurin G, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008;79:52-56.
19. US Food and Drug Administration. Mitoxantrone Hydro-chloride (marketed as Novantrone and generics)\Health-care Professional Sheet. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/ucm126445.htm. Accessed August 20, 2009.
20. Olindo S, Guillon B, Helias J, Phillibert B, Magne C, Feve JR. Decrease in heart ventricular ejection fraction during multiple sclerosis. Eur J Neurol 2002;9:287-291.
21. Tremlett H, Seemuller S, Zhao Y, Yoshida EM, Oger JD, Petkau J. Liver test abnormalities in multiple sclerosis: findings from placebo-treated patients. Neurology 2006; 67:1291-1293.